Gonadotropin-releasing hormone antagonist: how good is the new hope?

被引：11

作者：

Albano, C ^{[1
]}

Platteau, P ^{[1
]}

Devroey, P ^{[1
]}

机构：

[1] Dutchspeaking Brussels Free Univ, Ctr Reprod Med, B-1090 Brussels, Belgium

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2001年 / 13卷 / 03期

关键词：

D O I：

10.1097/00001703-200106000-00002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers, such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved, Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit over gonadotropin-releasing hormone antagonists for myoma and hormone-related disorders. Curr Opin Obstet Gynecol 13:257-262. (C) 2001 Lippincott Williams & Wilkins.

引用

页码：257 / 262

页数：6

共 52 条

[21] Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers [J].

Gründker, C ;

Völker, P ;

Schulz, KD ;

Emons, G .

GYNECOLOGIC ONCOLOGY, 2000, 78 (02) :194-202

[22] REPRODUCTIVE ENDOCRINE AND ANAPHYLACTOID PROPERTIES OF AN LHRH-ANTAGONIST, ORF-18260 [AC-DNAL1(2),4FDPHE2,D-TRP3,D-ARG6]-GNRH [J].

HAHN, DW ;

MCGUIRE, JL ;

VALE, WW ;

RIVIER, J .

LIFE SCIENCES, 1985, 37 (06) :505-514

[23] Embryo implantation: the Rubicon for GnRH antagonists [J].

Hernandez, ER .

HUMAN REPRODUCTION, 2000, 15 (06) :1211-1216

[24] Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report [J].

Itskovitz-Eldor, J ;

Kol, S ;

Mannaerts, B .

HUMAN REPRODUCTION, 2000, 15 (09) :1965-1968

[25]

JONES HW, 1982, FERTIL STERIL, V38, P14

[26] INTRA-OVARIAN SITE FOR LUTEOLYTIC ACTION OF ESTROGEN IN RHESUS-MONKEY [J].

KARSCH, FJ ;

SUTTON, GP .

ENDOCRINOLOGY, 1976, 98 (03) :553-561

[27] GOSERELIN, A DEPOT GONADOTROPIN-RELEASING HORMONE AGONIST IN THE TREATMENT OF PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER [J].

KAUFMANN, M ;

JONAT, W ;

KLEEBERG, U ;

EIERMANN, W ;

JANICKE, F ;

HILFRICH, J ;

KREIENBERG, R ;

ALBRECHT, M ;

WEITZEL, HK ;

SCHMID, H ;

STRUNZ, P ;

SCHACHNERWUNSCHMANN, E ;

BASTERT, G ;

MAASS, H .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1113-1119

[28]

KETTEL LM, 1993, FERTIL STERIL, V60, P642

[29] High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles [J].

Kol, S ;

Lightman, A ;

Hillensjo, T ;

Devroey, P ;

Fauser, B ;

Tarlatzis, B ;

Mannaerts, B ;

Itskovitz-Eldor, J .

HUMAN REPRODUCTION, 1999, 14 (09) :2242-2244

[30]

Lamharzi N, 1998, INT J ONCOL, V12, P671

← 1 2 3 4 5 6 →